Exondys 51 (Eteplirsen) for Duchenne Muscular Dystrophy

Type: drug

Status: FDA Approved

Developer: Sarepta Therapeutics

Breakthrough Summary

No summary available.

Mechanism of Action

Details pending.

Year: 2026